

VU Research Portal

High-resolution screening of metabolite-like lead libraries

Falck, D.

2013

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Falck, D. (2013). *High-resolution screening of metabolite-like lead libraries*.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

Table of Contents

1. Introduction	8		
1.1 General Introduction	9		
1.1.1 Discovery of new active pharmaceutical ingredients	10		
a) Screening	10		
b) Metabolite-like lead libraries	10		
1.1.2 High-resolution screening	11		
1.1.3 Modification methods in metabolism studies	15		
a) Chemical oxidation	16		
b) Electrochemistry	17		
c) Biocatalytic approaches	17		
d) Photochemistry	18		
1.1.4 Structure elucidation in mixtures using mass spectrometry and nuclear magnetic resonance spectroscopy	18		
a) Mass spectrometry	18		
b) Nuclear Magnetic resonance spectroscopy	20		
1.2 Scope	29		
2. High-resolution screening platforms	34		
2.1 A practical guide to high-resolution screening	35		
2.1.1 The high-resolution screening platform	36		
a) Separation	36		
b) Flow splitting	39		
c) Bioassay	39		
d) MS detection	42		
2.1.2 Data analysis	43		
a) Differences between HTS and HRS	43		
b) Validation	46		
2.1.3 Conclusions	48		
2.2 Development of an on-line p38α mitogen-activated protein kinase binding assay and integration of LC–HR-MS	51		
Introduction	52		
Materials and Methods	53		
Materials	53		
Instrumentation	53		
Plate Reader Assay	54		
On-line Assay	54		
Results and Discussion	56		
Assay conditions optimization	56		
Validation of the p38 α binding assay	57		
High resolution screening of mixtures	61		
Semi-Quantitative affinity measurements	61		
Applicability and binding modes	62		
Conclusion	63		
Supplementary Material	65		
2.3 Development of on-line liquid chromatography–biochemical detection for soluble epoxide hydrolase inhibitors in mixtures	67		
Introduction	68		
Materials and Methods	69		
Materials	69		
			Liquid chromatography – biochemical detection (LC–BCD) system 69
			Determination of inhibitor potency 71
			Metabolite identification using mass spectrometry 71
			Buffer and compound solutions 71
			Plate reader measurements 71
			Microsomal incubations 72
		Results and Discussion	72
		Development of an LC–BCD system for the detection of sEH inhibitors	72
		Characterization of the LC–BCD system	73
		Application of LC-BCD on the analysis of metabolic mixtures of sEHs	75
		Conclusion	77
		Supplementary Material	79
3. Integration of modification methods and HRS work-flows for the study of metabolite-like lead libraries	80		
3.1 On-line electrochemistry–bioaffinity screening with parallel HR-LC–MS for the generation and characterization of modified p38α kinase inhibitors	81		
Introduction	82		
Materials and Methods	83		
Chemicals	83		
Instrumentation	83		
Optimization of electrochemical conversion	85		
Results and Discussion	85		
Conclusion	91		
Supplementary Material	93		
3.2 Combination of biotransformation by P450 BM3 mutants with on-line post-column bioaffinity and mass spectrometric profiling as a novel strategy to diversify and characterize p38α kinase inhibitors	97		
Introduction	98		
Materials and Methods	99		
Chemicals	99		
Expression and isolation of P450 BM3 mutants	99		
Selection of the P450 BM3 mutant library	100		
Biotransformation of TAK-715 by P450 BM3 mutants and human liver microsomes	100		
HRS analysis of biotransformation products of TAK-715 using the LC-p38 α kinase affinity/MS platform	100		
Large-scale production and isolation of biotransformation products by preparative HPLC	101		
Results and Discussion	102		
Biocatalysed synthesis of lead compounds from TAK-715 by P450 BM3 mutants; comparison to human liver metabolism	102		
Parallel on-line bioaffinity assay and mass spectrometry of TAK-715 biotransformation products produced by P450 BM3 M11 and HLM	103		
Preparative scale biosynthesis of TAK-715 biotransformation products	103		
Structure elucidation of TAK-715 biotransformation products	105		
Estimation of product affinity (IC ₅₀)	108		
Conclusion	109		
Supplementary Material	112		

3.3	Comparison of (bio-)transformation methods for the generation of metabolite-like compound libraries of p38α MAP kinase inhibitors using high-resolution screening	117	5.	High temperature liquid chromatography hyphenated with ESI-MS and ICP-MS detection for the structural characterization and quantification of halogen containing drug metabolites	188
3.3.1.	Introduction	118		Introduction	190
3.3.2.	Materials and Methods	119		Experimental	191
	1. Materials	119		5.2.1 Materials	191
	2. Chemical oxidation	119		5.2.2 Methods	191
	3. Photochemical modification	120		Results and Discussion	193
	4. Microsomal incubations	120		5.3.1 Solvent effect on electrospray ionization	193
	5. HRS analysis	120		5.3.2 Hyphenation of HTLC to ICP-MS	194
3.3.3	Results	121		5.3.3 Profiling bromine containing MAPK inhibitor VIII products	195
	1. Oxidation with hydrogen peroxide	123		5.3.4 Analysis of iodine containing SB-I and conversion products	195
	2. Photochemical modification	126		5.3.5 Response comparison of ICP-MS and ESI-MS	199
3.3.4	Discussion	128		Conclusion	201
	1. Comparison of compound modification methods	128		Supplementary Material	202
	2. Conversion products as metabolite standards	130			
3.3.5	Conclusion	131	6. Summary		204
	Supplementary Material	135	6.1	Conclusions and Perspectives	205
4.	Integrated structure elucidation approaches for high-resolution screening	144	6.2	Nederlandse Samenvatting	213
4.1	Tandem mass spectrometry study of p38 α kinase inhibitors and related substances	145	Appendix		218
	Introduction	146	I.	List of Publications	219
	Materials and Methods	147	II.	Curriculum Vitae	221
	Chemicals	147	III.	Acknowledgements	222
	Generation of related substances of p38 α kinase inhibitors	147			
	HRS platform: LC with parallel bioaffinity screening and high-resolution MS	147			
	Results	149			
	Structure elucidation of DMPIP conversion products	150			
	Structure elucidation of SB203580 conversion products	153			
	Structure elucidation of BIRB796 conversion products	156			
	Structure elucidation of TAK-715 conversion products	158			
	Occurrence of homolytic cleavages	164			
	Conclusion	164			
	Supplementary Material	167			
4.2	EC-SPE-stripline-NMR analysis of reactive products: A feasibility study	171			
	Introduction	172			
	Materials and Methods	174			
	Chemicals	174			
	Electrochemical conversion	174			
	On-line Solid Phase Extraction	174			
	Stripline chip, probe and microfluidics	174			
	Acquisition and processing	175			
	EC-SPE-stripline-NMR setup	176			
	Results and Discussion	176			
	Optimization of EC and SPE steps	176			
	SPE-stripline-NMR	177			
	EC-SPE-stripline-NMR	180			
	Conclusions and Perspectives	181			
	Supplementary Material	184			